959992-64-4

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 6-bromo-2H-pyrido[3,2-b][1,4]oxazine-4(3H)-carboxylate is used as a building block for the synthesis of other complex organic compounds. Its unique structure and properties make it a promising candidate for the development of new therapeutic agents.
Used in Organic Synthesis:
Tert-butyl 6-bromo-2H-pyrido[3,2-b][1,4]oxazine-4(3H)-carboxylate is used as a key intermediate in the synthesis of various organic compounds. Its presence of a tert-butyl group and a bromine atom allows for further functionalization and modification, leading to the creation of new materials with commercial value.

Upstream product

• 959992-62-2 6-bromo-3,4-dihydro-2H-pyrido[3,2-b] [1,4]oxazine 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant academic research and scientific papers

Triazolopyridazine derivative as well as preparation method, pharmaceutical composition and application thereof

The invention relates to triazolopyridazine derivatives as well as a preparation method, a pharmaceutical composition and application thereof. The invention provides a compound shown in a general formula (I), cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound, and a preparation method of the compound, the cis-trans isomers, the enantiomers, the diastereoisomers, the racemes, the solvates, the hydrates or the pharmaceutically acceptable salts or the prodrugs of the compound; preparation method thereof; pharmaceutical compositions containing the compounds, and the use of the compounds as alpha 5-GABAA receptor modulators, wherein R 1, R 2, and Z are as defined in the specification. pharmaceutical compositions containing the compounds and application of the compounds as alpha-5-GABAA receptor modulators, wherein R1, R2 and Z are as defined in the specification.

N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS

The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to a5b1 antagonists that also exhibit appropriate selectivity profile(s) against other integrins.